Integrating Bispecific Antibodies Into Clinical Practice
Panelists discuss how bispecifics, like teclistamab, are administered at their institutions, the monitoring of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) during step-up dosing, and strategies to improve care transitions between academic centers and community practices. They also highlight the potential for outpatient administration of bispecifics, as seen in the OPTec and Ambulatory Teclistamab studies, emphasizing the benefits of patient convenience and safety.
Video content above is prompted by the following:
- How is the step-up and treatment doses for bispecifics administered at your institution? Are they administered in your clinic or in the community?
- How are patients monitored for CRS and ICANS during step-up doing?
- How can we improve the transition of care for patients receiving bispecifics between academic centers and community practices?
- Please comment on the following studies examining outpatient administration of bispecifics and how these strategies might be incorporated in practice: OPTec: Outpatient Step Up Administration of Teclistamab and Ambulatory Teclistamab Administration in R/R MM
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
